BCIQ Profiles

Company Profile Report

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug

Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from the hospital after satisfying discharge criteria under “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial

Read the full 500 word article

How to gain access

Continue reading with a
two-week free trial.